```html

Hepatitis E – A Comprehensive Medical Guide

Overview

Hepatitis E is an inflammation of the liver caused by infection with the hepatitis E virus (HEV). It is transmitted primarily through the fecal‑oral route, most often by drinking water or eating food contaminated with the virus. Unlike hepatitis A, which is common in many parts of the world, hepatitis E is endemic in regions with limited access to clean water and sanitation, especially South and Central Asia, sub‑Saharan Africa, and parts of Central America.

While anyone can become infected, the disease is most prevalent in:

• Adults aged 20‑50 years, especially men.
• Pregnant women in the third trimester (higher risk of severe disease).
• People with chronic liver disease or immunosuppression.

Global estimates suggest that WHO records roughly 20 million HEV infections each year, resulting in 3–4 million symptomatic cases and 44,000–70,000 deaths annually. In high‑income countries, most cases are travel‑related or caused by zoonotic strains (genotype 3) acquired from undercooked pork or deer meat.

Symptoms

Symptoms usually appear 2–8 weeks after exposure (incubation period). About 30–50 % of infected individuals remain asymptomatic. When symptoms do occur, they tend to develop gradually and can range from mild to severe.

Common clinical features

• Fever – low‑grade to high, often the first sign.
• Fatigue – persistent tiredness lasting weeks.
• Jaundice – yellowing of the skin and whites of the eyes caused by elevated bilirubin.
• Dark urine – due to bilirubin excretion.
• Pale stools – lack of bile pigment.
• Abdominal pain – typically in the right upper quadrant.
• Nausea & vomiting
• Loss of appetite

Less common / severe manifestations

• Acute liver failure (rare, but more common in pregnant women).
• Neurological symptoms – Guillain‑Barré‑like syndrome, encephalitis (very rare).
• Renal impairment – especially in immunocompromised hosts.
• Chronic infection – mainly genotype 3 in immunosuppressed patients (e.g., organ‑transplant recipients).

Causes and Risk Factors

Etiology

HEV is a non‑enveloped, single‑stranded RNA virus belonging to the Hepeviridae family. Four major genotypes affect humans:

• Genotype 1 – water‑borne, endemic in developing countries.
• Genotype 2 – similar to genotype 1 but rarer.
• Genotype 3 – zoonotic, transmitted via undercooked pork, wild boar, or deer; found in high‑income nations.
• Genotype 4 – primarily in East Asia, linked to both water‑borne and zoonotic spread.

Key risk factors

• Consumption of untreated or contaminated water.
• Eating raw or undercooked animal products (especially pork, venison, shellfish).
• Travel to endemic areas without proper food‑ and water‑safety precautions.
• Living in overcrowded conditions with poor sanitation.
• Pregnancy – especially third trimester, associated with a 5‑ to 10‑fold increase in mortality.
• Immunosuppression (e.g., HIV, chemotherapy, organ transplant) – predisposes to chronic infection.
• Pre‑existing chronic liver disease (HBV, HCV, alcoholic liver disease) – higher risk of severe hepatitis.

Diagnosis

Because the clinical picture overlaps with other viral hepatitides, laboratory testing is essential.

Serologic tests

• Anti‑HEV IgM – appears early (within 1–2 weeks of symptom onset) and indicates recent infection.
• Anti‑HEV IgG – develops later and persists for months to years, reflecting past exposure.

Molecular tests

• HEV RNA PCR – detects viral genome in blood or stool. Useful for confirming infection when serology is ambiguous and for monitoring chronic cases.

Other laboratory findings

• Elevated liver enzymes (ALT, AST) – usually 10–100 × upper limit of normal.
• Elevated bilirubin and alkaline phosphatase.
• Coagulation abnormalities (INR > 1.5) in severe cases.

Imaging & liver biopsy

Imaging (ultrasound, CT) is not diagnostic but helps assess liver size, exclude biliary obstruction, or evaluate for complications such as portal hypertension. Liver biopsy is rarely needed, reserved for atypical presentations or when chronic infection is suspected.

Treatment Options

For most immunocompetent adults, hepatitis E is self‑limiting and resolves within 4–6 weeks without specific antiviral therapy. Management focuses on supportive care and monitoring for complications.

Supportive care

• Rest and adequate hydration.
• Fever control with acetaminophen (avoid NSAIDs if liver function is markedly impaired).
• Nutrition: small, frequent meals; avoid alcohol and hepatotoxic substances.

Antiviral therapy

Antivirals are reserved for:

• Severe acute hepatitis (e.g., rising INR, encephalopathy).
• Pregnant women with fulminant disease.
• Chronic infection in immunocompromised patients.

Evidence supports the use of ribavirin (600‑1000 mg/day) for 3 months, achieving viral clearance in >80 % of chronic cases. CDC notes that interferon‑α has limited role due to side‑effects.

Hospitalization

Indications include:

• Acute liver failure (INR ≥ 1.5, encephalopathy).
• Severe dehydration or electrolyte imbalance.
• Pregnancy complications.
• Concurrent severe comorbidities.

Liver transplantation

Rare, but considered for fulminant liver failure unresponsive to medical therapy. Outcomes are comparable to transplantation for other causes of acute liver failure.

Living with Hepatitis E

Even after acute illness resolves, patients may have lingering fatigue and mild liver enzyme elevation. Here are practical tips for daily life:

• Nutrition: Emphasize a balanced diet rich in fruits, vegetables, lean protein, and whole grains. Limit saturated fat and avoid alcohol completely while the liver recovers.
• Hydration: Aim for 2‑3 L of water daily unless fluid restriction is ordered.
• Medication review: Discuss all over‑the‑counter and prescription drugs with your physician; many are metabolized by the liver.
• Rest: Gradually resume normal activities; avoid heavy lifting or intense exercise for at least 2 weeks after symptom resolution.
• Follow‑up labs: Repeat liver function tests 2–4 weeks after recovery to ensure normalization.
• Pregnancy planning: Women who have had hepatitis E should be counseled about the risks in future pregnancies and advised to avoid high‑risk foods and unsafe water.

Prevention

Because HEV transmission is largely environmental, public health measures are crucial.

Personal precautions

• Drink only treated, boiled, or bottled water when traveling to endemic areas.
• Wash fruits and vegetables thoroughly with safe water.
• Avoid raw or undercooked pork, organ meats, deer, and shellfish.
• Practice good hand hygiene—wash hands with soap and clean water after using the toilet and before handling food.
• Pregnant women should be especially vigilant about food and water safety.

Community & policy measures

• Improve water treatment and sewage systems (WHO recommends safe drinking water standards).
• Vaccination: A recombinant HEV vaccine (HEV 239, marketed as Hecolin) is licensed in China and shows >95 % efficacy; it is not yet globally available but may become part of travel‑medicine recommendations.
• Health education campaigns focusing on food safety and sanitation.

Complications

Although most infections are mild, certain groups can develop serious outcomes.

• Acute liver failure – mortality up to 20 % in the general population; exceeds 30 % in pregnant women.
• Chronic hepatitis E – reported in 1‑2 % of acute cases, predominantly in immunosuppressed hosts; may progress to cirrhosis.
• Extra‑hepatic manifestations – renal dysfunction, pancreatitis, neurologic syndromes (e.g., neuralgic amyotrophy).
• Vertical transmission – intra‑uterine infection can cause fetal loss, preterm birth, or neonatal hepatitis.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, WHO, NIH (NIH National Institute of Allergy and Infectious Diseases), Cleveland Clinic, Lancet Infectious Diseases (2022), International Journal of Infectious Diseases (2023).

```